英菲格拉替尼(Infigratinib)各版本的价格

Infigratinib is a targeted therapy indicated for the treatment of adult patients with previously treated unresectable locally advanced or metastatic cholangiocarcinoma confirmed to have fibroblast growth factor receptor 2 (FGFR2) fusions or other rearrangements.

Prices of various versions of generic versions of Infigratinib

Infigratinib has not yet been officially launched in China. The generic version produced by Lucius Pharmaceuticals in Laos is currently a more common version, with a specification of 100mg*21 capsules/box and a price of approximately US$471. This price is more economical than the original drug, providing patients with an affordable choice.

After understanding the drug price, patients also need to pay attention to the possible interactions between infigratinib and other drugs to avoid affecting the efficacy or increasing the risk of adverse reactions.

What drug interactions will Infigratinib have?

Infigratinib may interact with other drugs during treatment, affecting the efficacy or increasing side effects.

CYP3A inhibitors and inducers

Strong or moderate CYP3A inhibitors (such as itraconazole) may significantly increase the plasma concentration of infigratinib and increase the risk of adverse reactions. CYP3A inducers (such as rifampicin) will reduce drug concentration and weaken the therapeutic effect. When using these drugs, patients need to consult their doctor to adjust the dosage or switch to alternative drugs.

Gastric acid suppressors

Proton pump inhibitors (PPIs), H2 receptor antagonists, or antacids may reduce the absorption of infigratinib. If combined use is necessary, it is recommended that H2 receptor antagonists be used 2 hours before or 10 hours after taking infigratinib, and antacids should be used 2 hours before or 2 hours after taking infigratinib.

In addition to drug interactions, daily care of patients with cholangiocarcinoma is also crucial to treatment effectiveness and quality of life.

Daily care for patients with cholangiocarcinoma

Patients with cholangiocarcinoma need to pay special attention to physical care and living habits during treatment to reduce symptoms and improve treatment effects.

Diet management

Patients should choose light and easy-to-digest foods and avoid high-fat, spicy and irritating diets. Eating small and frequent meals can help reduce the digestive burden while ensuring adequate nutritional intake.

Symptom monitoring

During treatment, blood phosphorus levels, liver function and vision changes need to be checked regularly. If symptoms such as fatigue, abdominal pain, blurred vision and other symptoms occur, you should communicate with your doctor in time and adjust the medication plan if necessary.

Psychological support

The treatment process for cholangiocarcinoma may be accompanied by psychological stress. Patients can relieve anxiety and maintain a positive attitude by communicating with family, friends or professional psychological counselors.

Infigratinib may cause some side effects, such as nail toxicity, dry mouth, fatigue, etc. Patients need to pay close attention to their body's reactions during medication and promptly report abnormalities to their doctors in order to receive appropriate intervention and support.